A 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9–26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16–26 years of age, showed that the 9vHPV vaccine was generally well tolerated. Additional safety analyses were conducted to include the results of new clinical studies. The safety profile of the 9vHPV vaccine in prior qHPV vaccine recipients (n = 3756 from 1 randomized controlled trial and 2 open-label extension studies) and young men (n = 248 9vHPV and n = 248 qHPV vaccine recipients from 1 randomized controlled trial) was evaluated. Vaccine was administered as a 3-dose regimen (at Day 1 and Months 2 and 6), and adverse events (AEs) were monitored. The most common AEs were injection-site events (91.1% and 79.0% in prior qHPV vaccine recipients and young men, respectively), the majority of which were mild. Discontinuations due to an AE were rare (0.2% and 0.0% among prior qHPV vaccine recipients and young men, respectively). In young men, the AE profile of the 9vHPV vaccine was generally similar to that of the qHPV vaccine. Overall, the 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients and in young men, with an AE profile generally consistent with that previously reported with the broader clinical program.
Cervical smears from 516 women were investigated cytologically and for the presence of papilloma virus (HPV) type 16/18 DNA sequences. From the cytologically normal smears (Pap I, II, IIw) 57/424 (13%) 16/18 were found HPV positive and from the pathological ones (Pap III, IIID, IVa, IVb, V), 30/92 (33%). The age prevalence of the HPV infection--provided a cytologically normal smear--appears compatible with the period of sexual activity, but persistence of the HPV infection has to be considered as a complicating factor. Our investigations on successive smears nevertheless permit the hypothesis that an HPV infection may disappear. The use of biotin-labeled nucleic acid probes yields results at least as reliable as those obtained with radioactive probes. The test for HPV positivity appears at present to be of limited diagnostic and prognostic benefit, particularly for the individual case. Investigations on fundamental oncogenic mechanisms are a different matter.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.